Am­gen pulls ahead in sprint to­wards CGRP ap­proval with promis­ing PhI­II mi­graine da­ta

The fron­trun­ner in the race to com­mer­cial­ize CGRP mi­graine med­ica­tions just picked up some added mo­men­tum. Am­gen $AMGN has pub­lished promis­ing Phase III da­ta that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER